Metformin as a potential disease-modifying drug in osteoarthritis: a systematic review of pre-clinical and human studies.
Y Z Lim, Y Wang, M Estee...
https://pubmed.ncbi.nlm.nih.gov/35597372/Actively Recruiting
Led by Brigham and Women's Hospital · Updated on 2026-10-15
512
Participants Needed
9
Research Sites
52 weeks
Total Duration
Researchers are evaluating whether metformin can reduce pain and delay the onset of post-traumatic osteoarthritis PTOA after anterior cruciate ligament ACL reconstruction. This study compares metformin to a placebo in younger adults who have experienced ACL injuries. PTOA is a common, early-onset form of osteoarthritis resulting from joint injuries like ACL tears, affecting many working-age individuals and leading to significant quality of life and economic impacts. Participants will be randomly assigned to receive either metformin extended-release tablets or matching placebo tablets. The study drug is taken orally once daily for one year, starting at 500 mg and increasing to a maximum of 1500 mg daily as tolerated. All participants will follow standard postoperative physical therapy after ACL reconstruction. This phase 2, double-blind, placebo-controlled trial aims to test metformins ability to delay PTOA development and reduce knee pain. During the study, participants will complete questionnaires assessing knee pain and function at multiple time points up to 24 months after surgery. MRI scans will evaluate cartilage health at 24 months. Researchers will also track knee symptoms, activity levels, mental health, and physical tests such as walking speed and strength. The main outcomes include average knee pain scores and MRI cartilage scores to assess metformins potential effect on PTOA progression.
CONDITIONS
Preventing Injured Knees From osteoArthritis: Severity Outcomes
F
Faith Selzer, PhD
D
Daniel J Betensky, AB
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Brigham and Women's Hospital
Lead Sponsor
Arthritis Foundation
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Metformin, escalating to 1500 mg/day | Placebo (matching escalating dose) | Standard care without disease‑modifying drug |
|---|---|---|---|
| What it is | Extended‑release metformin taken orally, starting at 500 mg daily and increased by 500 mg every 5 days up to 1500 mg/day, taken for up to 12 months during post‑ACL reconstruction | Matching placebo tablets following the same dose escalation schedule as metformin, up to 1500 mg/day for up to 12 months | Usual management after ACL reconstruction without any investigational disease‑modifying medication |
| Primary use | Being tested to prevent or slow progression of post‑traumatic knee osteoarthritis after ACL reconstruction | Control comparator matching metformin to evaluate its disease‑modifying potential | Represents current rehabilitation‑focused care without pharmacologic OA prevention |
| How it is given or performed | Oral extended‑release tablet, taken once daily, dose increased stepwise every 5 days to reach up to 1500 mg/day | Oral placebo tablet matching active treatment schedule, taken once daily with dose increases every 5 days up to matching 1500 mg equivalent | Rehabilitation and physical therapy following standard ACL reconstruction protocols, without daily pharmacologic dosing |
| Evidence status | Efficacy as a disease‑modifying agent after ACL reconstruction is currently under investigation in this randomized trial | Placebo arm provides control but has no known effect on osteoarthritis progression | No proven pharmacologic agent currently used to prevent knee osteoarthritis after ACL reconstruction |
| Important limitations | Potential drug‑related side effects and tolerability of dose escalation are under study | Placebo arm offers no therapeutic effect and only serves for comparison | Standard care does not include disease‑modifying agents, limiting ability to compare drug benefit to current practice |
| Patient impact | Unknown—trial is evaluating whether metformin can reduce pain or structural progression of osteoarthritis | No impact beyond placebo; serves to assess investigational agent’s effect | Current standard care may improve short‑term recovery and function but does not explicitly slow osteoarthritis progression |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 year
Participants take either metformin or placebo tablets once daily for one year while following standard physical therapy after ACL reconstruction.
Regular visits during treatment
Duration - Up to 24 months
Participants complete knee pain questionnaires and undergo MRI scans to assess joint health up to 24 months after surgery.
Multiple assessments at scheduled intervals
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Y Z Lim, Y Wang, M Estee...
https://pubmed.ncbi.nlm.nih.gov/35597372/Yuanyuan Wang, Sultana Monira Hussain, Anita E Wluka...
https://pubmed.ncbi.nlm.nih.gov/31126352/Thomas D Brown, Richard C Johnston, Charles L Saltzman...
https://pubmed.ncbi.nlm.nih.gov/17106388/Douglas Adams, David S Logerstedt, Airelle Hunter-Giordano...
https://pubmed.ncbi.nlm.nih.gov/22402434/Alexander W Brinlee, Scott B Dickenson, Airelle Hunter-Giordano...
https://pubmed.ncbi.nlm.nih.gov/34903114/Global Burden of Disease Study 2013 Collaborators
https://pubmed.ncbi.nlm.nih.gov/26063472/Abbey C Thomas, Tricia Hubbard-Turner, Erik A Wikstrom...
https://pubmed.ncbi.nlm.nih.gov/27145096/Cale A Jacobs, Morgan H Jones, Jamie E Collins...
https://pubmed.ncbi.nlm.nih.gov/39867299/Brigham and Women's Hospital
Lead Sponsor
Arthritis Foundation
Collaborating Sponsor